PHiD‐CV11in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Adverse effects · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1 [0.8, 1.27]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.66 [1.07, 6.59]
Studies not reported
Low
All‐cause mortality · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes mortality compared with rituximab (very low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.44 [0.11, 1.81]
Studies not reported
Very low
Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.22 [0.03, 1.6]
Studies not reported
Very low
Remission for at least 24 weeks · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher remission for at least 24 weeks compared with placebo (low certainty).
1 finding from 1 review
RR 9.5 [2.3, 39.21]
Studies not reported
Low
Flare‐ups or relapse (continuous) · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any severe AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 1.78 [0.2, 16.1]
Studies not reported
Very low
Withdrawals due to adverse events · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any withdrawals due to AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 2.7 [0.13, 58.24]
Studies not reported
Very low
Durable remission · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty).
1 finding from 1 review
RR 13 [1.75, 96.33]
Studies not reported
Low
Relapse · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab probably leads to lower disease relapse compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.68 [0.53, 0.86]
Studies not reported
Moderate